Hiroyuki Konishi

Hiroyuki Konishi

Auto-generated profile, based on publicly available information

Hiroyuki Konishi

Department of Functional Anatomy and Neuroscience Nagoya University Graduate School of Medicine Nagoya Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKoichiro Haruwaka
Koichiro Haruwaka
AIAko Ikegami
Ako Ikegami
YTYoshihisa Tachibana
Yoshihisa Tachibana
NONobuhiko Ohno
Nobuhiko Ohno
HKHiroyuki Konishi
Hiroyuki Konishi
HWHiroaki Wake
Hiroaki Wake
Microglia survey brain parenchyma, responding to injury and infections. Microglia also respond to systemic disease, but the role of blood–brain barrier (BBB) integrity in this process remains unclear. Using simultaneous in vivo imaging, we demonstrated that systemic inflammation induces CCR5-dependent migration of brain resident microglia to the cerebral vasculature. Vessel-associated microglia initially maintain BBB integrity via expression of the tight-junction protein Claudin-5 and make physical contact with endothelial cells. During sustained inflammation, microglia phagocytose astrocytic end-feet and impair BBB function. Our results show microglia play a dual role in maintaining BBB integrity with implications for elucidating how systemic immune-activation impacts neural functions.

6 August 2018 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
HKHiroyuki Konishi
Hiroyuki Konishi
HKHiroshi Kiyama
Hiroshi Kiyama
Microglia are activated after neuronal injury and in neurodegenerative diseases, and trigger neuroinflammation in the central nervous system (CNS). Microglia-derived neuroinflammation has both beneficial and detrimental effects on neurons. Because the timing and magnitude of microglial activation is thought to be a critical determinant of neuronal fate, understanding the molecular mechanisms underlying microglial activation is required to enable establishment of microglia-targeted therapies for neural diseases. Plasma membrane receptors play primary roles as activators of microglia and in this review, we focus on a receptor complex involving triggering receptor expressed on myeloid cells 2 (TREM2) and DNAX-activating protein of 12 kDa (DAP12), both of which are causative genes for Nasu-Hakola disease, a dementia with bone cysts. Recent transcriptome approaches demonstrated TREM2/DAP12 signaling as the principal regulator that transforms microglia from a homeostatic to a neural disease-associated state. Furthermore, animal model studies revealed critical roles for TREM2/DAP12 in the regulation of microglial activity, including survival, phagocytosis, and cytokine production, not only in Alzheimer's disease but also in other neural diseases, such as Parkinson's disease, demyelinating disease, ischemia, and peripheral nerve injury. Intriguingly, while TREM2/DAP12-mediated microglial activation is detrimental for some diseases, including peripheral nerve injury, it is beneficial for other diseases. As the role of activated microglia differs among disease models, TREM2/DAP12 signaling may result in different outcomes in different diseases. In this review we discuss recent perspectives on the role of TREM2/DAP12 in microglia and their contribution to neural diseases.

22 September 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
HKHiroyuki Konishi
Hiroyuki Konishi
TOTakayuki Okamoto
Takayuki Okamoto
YHYuichiro Hara
Yuichiro Hara
OKOkiru Komine
Okiru Komine
HTHiromi Tamada
Hiromi Tamada
HKHiroshi Kiyama
Hiroshi Kiyama
Microglia are the principal phagocytes that clear cell debris in the central nervous system (CNS). This raises the question, which cells remove cell debris when microglial phagocytic activity is impaired. We addressed this question using Siglech dtr mice, which enable highly specific ablation of microglia. Non‐microglial mononuclear phagocytes, such as CNS‐associated macrophages and circulating inflammatory monocytes, did not clear microglial debris. Instead, astrocytes were activated, exhibited a pro‐inflammatory gene expression profile, and extended their processes to engulf microglial debris. This astrocytic phagocytosis was also observed in Irf8 ‐deficient mice, in which microglia were present but dysfunctional. RNA‐seq demonstrated that even in a healthy CNS, astrocytes express TAM phagocytic receptors, which were the main astrocytic phagocytic receptors for cell debris in the above experiments, indicating that astrocytes stand by in case of microglial impairment. This compensatory mechanism may be important for the maintenance or prolongation of a healthy CNS.

26 October 2016 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MKMasaaki Kobayashi
Masaaki Kobayashi
HKHiroyuki Konishi
Hiroyuki Konishi
ASAkira Sayo
Akira Sayo
TTToshiyuki Takai
Toshiyuki Takai
HKHiroshi Kiyama
Hiroshi Kiyama
Neuropathic pain afflicts millions of people, and the development of an effective treatment for this intractable pain is an urgent issue. Recent evidence has implicated microglia in neuropathic pain. The present study showed that the DNAX-activating protein of 12 kDa (DAP12) and its associated “triggering receptor expressed on myeloid cells 2” (TREM2) were predominantly expressed by microglia in the dorsal horn after spinal nerve injury, revealing a role for TREM2/DAP12 signaling in neuropathic pain. Nerve injury-induced proinflammatory cytokine expression in microglia and pain behaviors were significantly suppressed inDap12-deficient mice. Furthermore, intrathecal administration of TREM2 agonistic antibody induced proinflammatory cytokine expression, as well as neuropathic pain, in mice without nerve injury. The agonistic antibody induced proinflammatory responses and neuropathic pain was not observed inDap12-deficient mice. Together, these results suggest that TREM2/DAP12-mediated signals in microglia exacerbate nerve injury-induced neuropathic pain by inducing proinflammatory cytokine secretion from microglia. Suppression of DAP12-mediated signals could be a therapeutic target for neuropathic pain.SIGNIFICANCE STATEMENTRecent studies have revealed that activated microglia in the spinal dorsal horn exacerbate neuropathic pain, which has suggested that suppression of microglial activity should be considered as a therapeutic target. However, only a few molecules have been identified as regulators of microglial activity. In this study, we focused on a receptor complex of TREM2 and DAP12, both of which are expressed by microglia and have been implicated in the pathogenesis of Alzheimer's disease, and demonstrated that TREM2/DAP12 signaling promoted proinflammatory responses in microglia and exacerbates neuropathic pain. The present results revealed the functional significance of TREM2/DAP12 signaling in microglial activation after neuronal injury, and could help in the development of treatments for neuropathic pain and neurodegenerative diseases.

24 August 2017 in Glia
Verified
Journal Article
Open access
PDF file
HKHiroyuki Konishi
Hiroyuki Konishi
MKMasaaki Kobayashi
Masaaki Kobayashi
TKTaikan Kunisawa
Taikan Kunisawa
KIKenta Imai
Kenta Imai
ASAkira Sayo
Akira Sayo
HKHiroshi Kiyama
Hiroshi Kiyama
Several types of myeloid cell are resident in the CNS. In the steady state, microglia are present in the CNS parenchyma, whereas macrophages reside in boundary regions of the CNS, such as perivascular spaces, the meninges and choroid plexus. In addition, monocytes infiltrate into the CNS parenchyma from circulation upon blood–brain barrier breakdown after CNS injury and inflammation. Although several markers, such as CD11b and ionized calcium‐binding adapter molecule 1 (Iba1), are frequently used as microglial markers, they are also expressed by other types of myeloid cell and microglia‐specific markers were not defined until recently. Previous transcriptome analyses of isolated microglia identified a transmembrane lectin, sialic acid‐binding immunoglobulin‐like lectin H (Siglec‐H), as a molecular signature for microglia; however, this was not confirmed by histological studies in the nervous system and the reliability of Siglec‐H as a microglial marker remained unclear. Here, we demonstrate that Siglec‐H is an authentic marker for microglia in mice by immunohistochemistry using a Siglec‐H‐specific antibody. Siglec‐H was expressed by parenchymal microglia from developmental stages to adulthood, and the expression was maintained in activated microglia under injury or inflammatory condition. However, Siglec‐H expression was absent from CNS‐associated macrophages and CNS‐infiltrating monocytes, except for a minor subset of cells. We also show that the Siglech gene locus is a feasible site for specific targeting of microglia in the nervous system. In conclusion, Siglec‐H is a reliable marker for microglia that will allow histological identification of microglia and microglia‐specific gene manipulation in the nervous system.

10 February 2022 in Glia
Verified
Journal Article
Open access
PDF file
HKHiroyuki Konishi
Hiroyuki Konishi
Schuichi KoizumiSchuichi Koizumi
Schuichi Koizumi
HKHiroshi Kiyama
Hiroshi Kiyama
Elimination of dead or live cells take place in both a healthy and diseased central nervous system (CNS). Dying or dead cells are quickly cleared by phagocytosis for the maintenance of a healthy CNS or for recovery after injury. Live cells or parts thereof, such as the synapses and myelin, are appropriately eliminated by phagocytosis to maintain or refine neural networks during development and adulthood. Microglia, the specific population of resident macrophages in the CNS, are classically considered as primary phagocytes; however, astrocytes have also been highlighted as phagocytes in the last decade. Phagocytic targets and receptors are reported to be mostly common between astrocytes and microglia, which raises the question of how astrocytic phagocytosis differs from microglial phagocytosis, and how these two phagocytic systems cooperate. In this review, we address the consequences of astrocytic phagocytosis, particularly focusing on these elusive points.